Cytokines and the Risk of Infection in Liver Cirrhosis

Medical University of Graz150 enrolled

Overview

The aim of this study is to test whether the oscillation of cytokine concentrations in serum is able to predict the development of infection in patients with liver cirrhosis.

Patients with liver cirrhosis frequently develop bacterial, viral or fungal infections which are the main trigger for decompensation of cirrhosis and development of complications and thereby infection hugely impacts morbidity and mortality in these patients. However, there is no clinical test available that allows rapid, on-site decision making if a patient is likely to develop an infection. The purpose of this study is to measure cytokines interleukin (IL) 6, IL8, IL10 and TNFalpha in patients with liver cirrhosis over a long follow-up period and test whether these inflammatory markers are able to predict the occurrence of infection before it becomes clinically significant. For this purpose, one hundred fifty consecutive patients with diagnosis of liver cirrhosis will be followed bi-monthly for 18 months. Blood samples will be collected for the cytokine measurements and infection cases will be reported at each study visit.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Liver Cirrhosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with clinical, radiological and/or histological evidence of liver cirrhosis * Age above 18 (inclusive) at the time of screening * Able and willing to give written informed consent and to comply with the requirements of the study Exclusion Criteria: * Infection during the last 14 days before screening * Gastrointestinal bleeding within the last 14 days before screening * Antibiotic therapy at the time of screening (except prophylaxis of spontaneous bacterial peritonitis) * Shock or cardiac failure requiring inotrope treatment at the time of screening * Hepatic encephalopathy grade \>2 * Findings suggestive of organic nephropathy or a serum creatinine level of more than 2 mg/dl * Human immunodeficiency virus infection at time of inclusion * Use of immunomodulating agents within one month prior to screening (e.g. steroids) * Any disease (e.g., advanced neoplasia) that could affect the short-term prognosis * Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject

Locations (1)

Medical University Graz

Graz, Styria, Austria

Outcomes

Primary Outcomes

Clinically significant infection requiring antibiotic, antiviral or antifungal treatment and hospitalisation.

Time frame: 18 months

Secondary Outcomes

All infections

Time frame: 18 months

Hospitalisation for reasons other than infection

Time frame: 18 months

Duration of hospitalisation

Time frame: 18 months

Mortality

Time frame: 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.